Historical Stock Chart
2 Months : From Jun 2019 to Aug 2019
By Chris Wack
Baxter International Inc. (BAX) said Monday the U.S. Food and Drug Administration approved Myxredlin insulin for IV infusion.
The medication company said Myxredlin is indicated for use as a short-acting human insulin to improve glycemic control in adults and pediatric patients with diabetes mellitus.
Baxter said it expects Myxredlin to be available in the U.S. before the end of 2019.
Write to Chris Wack at email@example.com
(END) Dow Jones Newswires
July 22, 2019 09:34 ET (13:34 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.